Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.55 |
| ▸ | APEX1 | P27695 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | ATF4 | P18848 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17019881 | 0.79 | POLB (0.78) | POLBBLMTDP1ALOX15MAPT | |
| SCHEMBL13666599 | 0.78 | CYP19A1 (0.77) | CYP19A1POLBNOTUMMAPTALDH1A1 | |
| SCHEMBL2658779 | 0.76 | QPCT (0.56) | CYP19A1POLBTBXAS1NOTUMMEN1 | |
| SCHEMBL28698662 | 0.75 | CYP19A1 (0.55) | CYP19A1POLBNOTUMMAPTALDH1A1 | |
| SCHEMBL13666464 | 0.75 | CYP19A1 (1.00) | CYP19A1NOTUM | |
| SCHEMBL339492 | 0.74 | ALOX15 (0.81) | NR4A1APEX1ALOX15MAPTALDH1A1 | |
| SCHEMBL10447781 | 0.74 | NOTUM (0.78) | CYP19A1NOTUM | |
| SCHEMBL9756474 | 0.74 | TBXAS1 (0.49) | CYP19A1TBXAS1NOTUMFFAR1ITGB3 | |
| SCHEMBL462839 | 0.74 | NOTUM (0.56) | CYP19A1NR4A1APEX1POLBTDP1 | |
| SCHEMBL4646462 | 0.74 | TBXAS1 (0.47) | POLBTDP1TBXAS1ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| EP-2448581-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002816-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | CYP19A1 2856/4885NR4A1 3779/4885APEX1 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.